Patent application number | Description | Published |
20080234175 | Process for Designing Inhibitors of Influenza Virus Structural Protein 1 - Disclosed are methods and compositions useful in identifying inhibitors of influenza virus, such as influenza A and B virus. Also disclosed are methods for preparing compositions for administration to animals, including humans infected with or to protect against influenza virus. | 09-25-2008 |
20100081126 | PROCESS FOR DESIGNING INHIBITORS OF INFLUENZA VIRUS STRUCTURAL PROTEIN-1 - Disclosed are methods and compositions useful in identifying inhibitors of influenza virus, such as influenza A and B virus. Also disclosed are methods for preparing compositions for administration to animals, including humans infected with or to protect against influenza virus. | 04-01-2010 |
20100107264 | DEVELOPMENT OF INFLUENZA A ANTIVIRALS - The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced. | 04-29-2010 |
20100247569 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 09-30-2010 |
20100291128 | NOVEL COMPOSITIONS AND VACCINES AGAINST INFLUENZA A AND INFLUENZA B INFECTIONS - Novel models of interactions of the Nonstructural Protein of influenza A and influenza B viruses (NS1A and NS1B, respectively) with dsRNA are presented. On the basis of the models, novel recombinant viruses and vaccines against influenza A and influenza B viruses are provided. | 11-18-2010 |
20140044745 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 02-13-2014 |
20140308307 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 10-16-2014 |
20150093405 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 04-02-2015 |